Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for GLAXO
Revenue projections for GLAXO

GLAXO's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 0.000000
forwardPE 37.897114
debtToEquity 2.091000
earningsGrowth 0.286000
revenueGrowth 0.097000
grossMargins 0.636390
operatingMargins 0.337110
trailingEps 60.250000
forwardEps 68.525000

GlaxoSmithKline Pharmaceuticals Limited's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.
GLAXO's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that GLAXO is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for GLAXO
Price projections for GLAXO

GlaxoSmithKline Pharmaceuticals Limited's present price, in comparison to its projections, indicates no evident risks or opportunities. This balanced scenario suggests a steady environment, where investors might choose to wait for more definitive indicators before altering their strategies.

Recommendation changes over time:

Recommendations trend for GLAXO
Recommendations trend for GLAXO


GlaxoSmithKline Pharmaceuticals Limited has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view GlaxoSmithKline Pharmaceuticals Limited as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.